Welcome to NOK Therapeutics
At NOK Therapeutics, we are dedicated to transforming cancer treatment and broadening patient access to cutting-edge therapeutic options. We do this by harnessing the power of autologous natural killer (NK) cell therapies to provide safer, more effective treatment options for patients worldwide.
Our Mission
To expand cancer patient access to cutting-edge, life-changing cellular therapies.
Cellular therapies have revolutionized the oncology treatment paradigm, offering robust therapeutic effects and, in some cases, even cures for patients with various cancers.
These therapies represent a significant advancement in precision medicine, harnessing the body’s own immune system to target and eliminate cancer cells more effectively than traditional treatments. However, the complexity of infusion protocols, including requirements like lymphodepletion, often restricts access to these transformative treatments.
At NOK Therapeutics, we are dedicated to overcoming these barriers. Our mission is to ensure that more cancer patients can benefit from the life-changing potential of cellular therapies, regardless of their previous treatment history or current health status.
Our Approach
Autologous Natural Killer (NK) Cell Therapy
Our approach centers on developing autologous NK cell therapies – NK cells derived from the patients themselves. This is our focus for two major reasons:
- First, NK cells are intrinsically safe, offering a therapeutic option that minimizes additional stress on patients who are already in a vulnerable state due to previous treatments.
- Second, unlike allogeneic NK or autologous T cell therapies, our autologous NK cells do not require lymphodepletion, a process that is often highly toxic and can disqualify many patients from receiving cellular therapies.
By eliminating the need for lymphodepletion, we significantly reduce treatment-related toxicity, making our therapies accessible to a broader range of patients, including those who might otherwise be excluded due to their health status.
Our Strategic Clinical Development
At NOK Therapeutics, we are applying the right technology to the right patient population. Our pipeline focuses on minimal residual disease (MRD)-positive situations and enhancing antibody-dependent cellular cytotoxicity (ADCC). Explore our innovative strategies and clinical development plans, below.
Company Leadership
Tamara Jovonovich, PhD
COO
20 years in pharmaceutical development; 15 FDA drug approvals.
Click to learn more.
Brian Cogley
CFO
>15 years leading companies in life sciences and financial services
Click to learn more.
Become An Investor
Visit out investor hub for company details and more information on how to join our team of investors.